ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 120 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,929 | -6.7% | 56,615 | +5.7% | 0.00% | – |
| Q2 2023 | $123,142 | -13.4% | 53,540 | +14.0% | 0.00% | – |
| Q1 2023 | $142,273 | +34.6% | 46,955 | +3.5% | 0.00% | – |
| Q4 2022 | $105,686 | +46.8% | 45,359 | +19.5% | 0.00% | – |
| Q3 2022 | $72,000 | -24.2% | 37,965 | +8.3% | 0.00% | – |
| Q2 2022 | $95,000 | +18.8% | 35,040 | +30.3% | 0.00% | – |
| Q1 2022 | $80,000 | -19.2% | 26,898 | +6.0% | 0.00% | – |
| Q4 2021 | $99,000 | -21.4% | 25,385 | -13.0% | 0.00% | – |
| Q3 2021 | $126,000 | +65.8% | 29,180 | +15.9% | 0.00% | – |
| Q2 2021 | $76,000 | -87.2% | 25,186 | -78.5% | 0.00% | – |
| Q4 2017 | $592,000 | -15.4% | 117,321 | +3.9% | 0.00% | – |
| Q3 2017 | $700,000 | +98.3% | 112,927 | +15.1% | 0.00% | – |
| Q2 2017 | $353,000 | +10.0% | 98,090 | -0.7% | 0.00% | – |
| Q1 2017 | $321,000 | – | 98,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |